44 completed, 11 recruiting, 7 terminated, 5 active not recruiting. 73 Phase 1, 25 Phase 2.
Follow Thrombocytosis: new trials by email Literature Review of Thrombocytosis trials Research Report on Thrombocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| Therapeutic RSK1 Targeting in Myeloid Malignancies PMD-026 - Myeloid Malignancy | Phase 1 | Recruiting | Washington University School of Medicine | 30 | 2026-05-20 | 2026-10-21 |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-11-13 |
| Safety and Tolerability of ZE74-0282 in Healthy Volunteers ZE74-0282-0001 or placebo - Healthy Volunteers | Phase 1 | Recruiting | Eilean Therapeutics AU Pty Ltd | 64 | 2026-04-16 | 2026-07-28 |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms INCA035784 - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 120 | 2025-10-01 | 2026-08-06 |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis JBI-802 - Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) | Phase 1 / Phase 2 | Recruiting | Jubilant Therapeutics Inc. | 30 | 2024-10-21 | 2026-06-03 |
| A Study of GLB-001 in Patients With Myeloid Malignancies GLB-001 - Polycythemia Vera, Essential Thrombocythemia | Phase 1 | Recruiting | Hangzhou GluBio Pharmaceutical Co., Ltd. | 108 | 2024-05-24 | 2025-08-19 |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Talazoparib, pacritinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 | Recruiting | Fox Chase Cancer Center | 24 | 2024-04-05 | 2024-05-03 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms INCA033989, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 290 | 2023-12-04 | 2026-04-17 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms INCA033989, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Active not recruiting | Incyte Corporation | 160 | 2023-09-25 | 2026-08-10 |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm Peptide-based vaccine, Poly ICLC - Myelofibrosis, Essential Thrombocythemia | Phase 1 | Active not recruiting | Marina Kremyanskaya | 7 | 2023-04-04 | 2026-09-28 |
| Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs CK0804 - Myelofibrosis | Phase 1 | Recruiting | Cellenkos, Inc. | 24 | 2022-12-27 | 2026-10-21 |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms N-Acetylcysteine - Myeloproliferative Neoplasm, MPN | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 27 | 2022-01-03 | 2026-03-10 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms INCB057643, Ruxolitinib - Myelofibrosis, Myelodysplastic Syndrome | Phase 1 | Active not recruiting | Incyte Corporation | 140 | 2021-02-23 | 2026-04-01 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 1 | Terminated | Astex Pharmaceuticals, Inc. | 20 | 2020-12-21 | 2024-08-02 |
| A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy APG-1252, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Withdrawn | Ascentage Pharma Group Inc. | 2020-12-15 | 2022-07-12 | |
| Study of Select Combinations in Adults With Myelofibrosis MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2020-11-30 | 2021-03-04 | |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Navitoclax, Ruxolitinib, Celecoxib - Myeloproliferative Neoplasm | Phase 1 | Active not recruiting | AbbVie | 85 | 2019-11-08 | 2025-02-14 |
| Dual Vaccine Trial in Myeloproliferative Neoplasms PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL, Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL - Polycythemia Vera, Essential Thrombocythemia | Phase 1 / Phase 2 | Completed | Inge Marie Svane | 9 | 2019-07-10 | 2023-07-13 |
Showing 20 of 73. Sign in to see all of them.
Thrombocythemia, Essential (68) · Primary Myelofibrosis (66) · Myeloproliferative Disorders (58) · Polycythemia Vera (57) · Leukemia, Myeloid, Acute (40) · Leukemia, Myelomonocytic, Chronic (36) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (34) · Myelodysplastic Syndromes (33) · Leukemia, Lymphocytic, Chronic, B-Cell (30) · Leukemia (28) · Burkitt Lymphoma (26) · Lymphoma, Follicular (26) · Lymphoma, Mantle-Cell (26) · Lymphoma, Non-Hodgkin (26) · Multiple Myeloma (26)
Hemic and Lymphatic Diseases (73) · Blood Platelet Disorders (72) · Bone Marrow Diseases (68) · Hematologic Diseases (68) · Hemorrhagic Disorders (68) · Blood Coagulation Disorders (67) · Neoplasms (61) · Neoplasms by Site (61) · Hematologic Neoplasms (58) · Bone Marrow Neoplasms (57) · Disease Attributes (45) · Leukemia, Myeloid (45) · Neoplasms by Histologic Type (45) · Pathologic Processes (45)
ruxolitinib (12) · Peripheral Blood Stem Cell Transplantation (9) · Cyclophosphamide (6) · Cyclosporine (6) · fludarabine phosphate (5) · Antilymphocyte Serum (4) · Busulfan (4) · Carboplatin (4) · Decitabine (4) · Filgrastim (4) · Methotrexate (4) · Cytarabine (3) · Etoposide (3) · Methylprednisolone (3) · Tacrolimus (3)
National Cancer Institute (NCI) (7) · Incyte Corporation (6) · Fred Hutchinson Cancer Center (4) · Eli Lilly and Company (3) · California Cancer Consortium (2) · Inge Marie Svane (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Northwestern University (2) · Novartis Pharmaceuticals (2) · OHSU Knight Cancer Institute (2) · AbbVie (1) · Alliance for Clinical Trials in Oncology (1) · Asan Medical Center (1) · Ascentage Pharma Group Inc. (1)
United States (61) · Australia (8) · Italy (8) · Germany (7) · United Kingdom (7) · Canada (6) · France (6) · Belgium (5) · Spain (5) · Denmark (4) · Japan (4) · China (2) · Netherlands (2) · Poland (2) · South Korea (2)
Ayalew Tefferi, MD (2) · Jacob H Grauslund, MD (2) · Jorge Cortes, MD (2) · Richard K. Burt, MD (2) · Ronald Hoffman, MD (2) · Todd M. Zimmerman, MD (2) · Alex Shalaurov, MD, PhD (1) · Amy W Zhou, M.D. (1) · Andrew Roberts, M.D. (1) · Angela Fleischman, MD, PhD (1) · Ann E. Woolfrey, MD (1)
PMID 15570084, PMID 20843246, PMID 22259028, PMID 22718840, PMID 24474568, PMID 25563429, PMID 25762180, PMID 26210442, PMID 26853648, PMID 27479177, PMID 28934680, PMID 29544547, PMID 30562587, PMID 31167802, PMID 32634234, PMID 33718228, PMID 36881782, PMID 36911725, PMID 37422688, PMID 37530627, PMID 38259250, PMID 39863139
2018 (2), P30CA015083 (2), U01CA062491 (2), 2019 (1), 2023 (1), P01CA018029 (1), P01CA108671 (1), P30CA006973 (1), P30CA016058 (1), P30CA016086 (1), P30CA016087 (1), P30CA023074 (1), P30CA033572 (1), P30CA036727 (1), P30CA072720 (1)